Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05453006 · ClinicalTrials.gov registry record · NA
HPV Self-Sampling in Somali Women (Isbaar Project)
A NA study of Cervical Cancer and Papillomavirus Infection, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 3,367
- Enrollment target
- 1
- Study location
NCT05453006: Completed NA study of Cervical Cancer and Papillomavirus Infection, sponsored by University of Minnesota.
NCT05453006 is a NA study of Cervical Cancer and Papillomavirus Infection that has completed, run by University of Minnesota. The registered enrollment target is 3,367 participants, above the 547-participant average among 144 other Cervical Cancer trials with a reported enrollment target (516% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05453006, a NA study of Cervical Cancer and Papillomavirus Infection, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,367 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to assess the effect of implementing HPV self-sampling in primary care on uptake of cervical cancer screening in 30-65 year old Somali women who are due for cervical cancer screening.
Primary Outcome
Difference-in-difference Cox proportional hazards regression to compare screening completion changes 12-months pre- /post-implementation in intervention versus control clinics, adjusting for age, screening history, and CDC social vulnerability index (SVI).
Conditions Studied
Interventions
- DEVICE COPAN 552c.80 FLOQSwab
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,367 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2025-05-19 |
| Phase | NA |
What the finished NCT05453006 record still lists
NCT05453006 is an interventional study that assigns participants to a tested intervention. Its 3,367 participants enrollment target places it among the larger protocols in the corpus, above the 547-participant average among 144 other Cervical Cancer trials with a reported enrollment target (516% higher).
The record links to 4 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which COPAN 552c.80 FLOQSwab is the first listed.
NCT05453006 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05453006 about?
NCT05453006 is a clinical study titled "HPV Self-Sampling in Somali Women (Isbaar Project)". This study plans to assess the effect of implementing HPV self-sampling in primary care on uptake of cervical cancer screening in 30-65 year old Somali women who are due for cervical cancer screening.
What is the current status of trial NCT05453006?
This trial is currently completed. It is a NA study. The enrollment target is 3,367 participants. The study started on 2023-02-20. Estimated completion is 2025-05-19.
What conditions does trial NCT05453006 study?
This clinical trial studies the following conditions: Cervical Cancer, Papillomavirus Infection, Uterine Diseases, Uterine Cervical Disease.
What interventions are being tested in trial NCT05453006?
The interventions under investigation include: COPAN 552c.80 FLOQSwab (DEVICE).
Who is sponsoring clinical trial NCT05453006?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05453006 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05453006's enrollment target sits among peer trials
3,367 5th of 144 higher than 140 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI